No new items were published in the sources we monitor on this date. The open consultations and hearings below remain current.
Federal Official Gazette
No updates.
ANS news
No updates.
Open public consultations
- CP 159. New social participation aimed at broadening the public debate on the effective implementation of the Health Plan Pricing and Price Adjustment Policy. Deadline: Jul 21, 2025 to Oct 19, 2025
- CP 162. Its objective is to receive contributions related to the proposed updates to the List of Health Procedures and Events (Rol). Deadline: Oct 9, 2025 to Oct 28, 2025.
Scheduled public hearings
- AP 60. Aims to collect contributions on the preliminary recommendation of non-incorporation for the following technology: (i) UAT 172 – Risankizumab for the treatment of adult patients with moderate to severe active ulcerative colitis after failure, refractoriness, relapse or intolerance to anti-TNF therapy. Date: Oct 17, 2025, from 9:30 a.m. to 11 a.m.
Open public calls for input
There is no open public call for input.
Open public calls
No updates.
Other news
– No updates.
Sources: Federal Official Gazette (DOU) and the ANS website. Press items link to the original article. This brief is for information only and does not constitute legal advice.